At baseline, 91% of patients were hepatitis B e antigen-positive and 85% had prior exposure to HBV therapy. COVID-19 is an emerging, rapidly evolving situation.Conflict-of-interest statement: The authors declare no conflicts of interest. 2020 Mar-Apr;10(2):150-154. doi: 10.1016/j.jceh.2019.04.002. Please enable it to take advantage of the complete set of features! 2010 Feb;52(2):176-82. doi: 10.1016/j.jhep.2009.11.007.
2013 Oct 21;19(39):6665-78. doi: 10.3748/wjg.v19.i39.6665.Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY.J Gastroenterol. One hundred six patients were enrolled; 101 patients completed 72 weeks of treatment.
Please enable it to take advantage of the complete set of features! Free PMC article Baishideng Publishing Group Inc. Epub 2014 Jan 23.Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E.Gastroenterology. Copyright © 2012 American Association for the Study of Liver Diseases. 2018 Dec;8(4):403-431. doi: 10.1016/j.jceh.2018.06.010.
Of… Treatment response was not affected by prior HBV treatment. 2019 Sep;39(9):835-846. doi: 10.1007/s40261-019-00802-8.Korean Association for the Study of the Liver (KASL).Korean Association for the Study of the Liver (KASL).Clin Mol Hepatol.
Name must be less than 100 characters
Tenofovir disoproxil fumarate is an acyclic nucleotide analogue of adenosine used in combination with other agents in the therapy of the human immunodeficiency virus (HIV) and as single agent in hepatitis B virus (HBV) infection.
2017 Nov 15;11(6):828-834. doi: 10.5009/gnl16484.World J Gastroenterol. A virologic response was observed in 89% (46/52) of patients who received tenofovir DF and 0% (0/54) of patients who received placebo (P < 0.001).
Hepatology. 2019 Jun;25(2):93-159. doi: 10.3350/cmh.2019.1002.
2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ.Gastroenterology.
Flow chart of the enrolled participants. eCollection 2013 Feb.Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B.J Clin Exp Hepatol. The primary endpoint was virologic response (HBV DNA <400 copies/mL) at week 72. CHB: Chronic hepatitis B; TDF: Tenofovir disoproxil fumarate.The mean changes in serum HBV DNA levels of the decompensated and compensated cirrhosis group. Wiley Unable to load your delegates due to an error Listing a study does not mean it has been … Unable to load your collection due to an error 2014 Apr;146(4):980-8. doi: 10.1053/j.gastro.2013.12.028.
2013 Mar 1;2(1):41-44. doi: 10.1002/cld.125. The mean Child-Turcotte-Pugh (CTP) score (8.0 ± 1.5 The changes of creatinine clearance (eGFR) during the tenofovir disoproxil fumarate therapy.
No patients met the safety endpoint of a 6% decrease in spine bone mineral density at week 72.
This study evaluated the safety and efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB). Epub 2018 Jun 26.
2015 Mar 7;21(9):2746-53. doi: 10.3748/wjg.v21.i9.2746.Drugs. CHB: Chronic hepatitis B; TDF: Tenofovir disoproxil… The mean changes in serum HBV DNA levels of the decompensated and compensated… The changes of the Child-Turcotte-Pugh and model for end-stage liver disease scores in… The changes of creatinine clearance (eGFR) during the tenofovir disoproxil fumarate therapy. Among patients with an alanine aminotransferase (ALT) level greater than the upper limit of normal at baseline, normalization of ALT occurred in 74% of patients receiving tenofovir DF and 31% of patients receiving placebo (P < 0.001).